CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Association of Abnormal Left Ventricular Functional Reserve With Outcome in Heart Failure With Preserved Ejection Fraction Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life SPECT and PET in ischemic heart failure Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

Clinical TrialDecember 8, 2020 Vol 142, Issue 23

JOURNAL:Circulation. Article Link

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

F Cosentino , CP Cannon , DZI Cherney et al. Keywords: ertugliflozin;T2DM; ASCVD, HF

Full Text PDF